Biostage, Inc. announced that it initiated start-up activities for its first clinical trial. The Phase 1, first-in-human study approved by the FDA will evaluate both safety and efficacy in up to ten patients requiring the removal of up to 6 cm of their esophagus (including cancer, trauma or birth defects) at up to five hospitals in the U.S. The primary endpoint is the development of a continuous biological neo-conduit at three months following implantation.
Harvard Apparatus Regenerative Technology Inc.
Equities
HRGN
US09074M2026
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.25 USD | -8.54% | -5.86% | -54.91% |
1st Jan change | Capi. | |
---|---|---|
-54.91% | 32.21M | |
+8.88% | 219B | |
+8.68% | 185B | |
+14.25% | 135B | |
+28.18% | 107B | |
+14.65% | 51.28B | |
+4.48% | 51.01B | |
+4.39% | 41.85B | |
+7.00% | 37.02B | |
+26.06% | 31.27B |
- Stock Market
- Equities
- HRGN Stock
- News Harvard Apparatus Regenerative Technology Inc.
- Biostage Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease